"2014-04-01+02:00"^^ . "0"^^ . "http://www.isvav.cz/projectDetail.do?rowId=LD14019"^^ . . . "Hlavn\u00EDm c\u00EDlem tohoto v\u00FDzkumn\u00E9ho projektu bude zv\u00FD\u0161it a roz\u0161\u00ED\u0159it poznatkovou z\u00E1kladnu pot\u0159ebnou pro porozum\u011Bn\u00ED mechanismu p\u016Fsoben\u00ED nov\u00FDch organokovov\u00FDch konjug\u00E1t\u016F a vyu\u017E\u00EDt tyto nov\u00E9 znalosti k v\u00FDvoji nov\u00FDch t\u0159\u00EDd oraganokovov\u00FDch slou\u010Denin s inovovan\u00FDm spektrem protin\u00E1dorov\u00E9 aktivity. C\u00EDlem tohoto projektu tedy bude reagovat na klinckou pot\u0159ebu nov\u00FDch terapeuticky p\u016Fsob\u00EDc\u00EDch l\u00E1tek s nov\u00FDm mechanismem p\u016Fsoben\u00ED. Organokovov\u00E9 slou\u010Deniny s du\u00E1ln\u00ED funkc\u00ED takov\u00E9 mo\u017Enosti nab\u00EDzej\u00ED, ale z\u00E1kladn\u00ED medic\u00EDnsk\u00E1 chemie a molekul\u00E1rn\u00ED a bun\u011B\u010Dn\u00E1 farmakologie a biologie t\u011Bchto slou\u010Denin byla doposud m\u00E1lo prozkoum\u00E1na. Pokrok v terapii n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED vy\u017Eaduje z\u00EDsk\u00E1vat detailn\u00ED informace o procesech, kter\u00E9 mohou p\u0159isp\u011Bt k selektivn\u00EDmu po\u0161kozen\u00ED a smrti n\u00E1dorov\u00FDch bun\u011Bk a z\u00E1rove\u0148 ponechat norm\u00E1ln\u00ED bu\u0148ky nepo\u0161kozen\u00E9. Budou studov\u00E1ny unik\u00E1tn\u00ED zp\u016Fsoby modifikace biomolekul c\u00EDlen\u011B navr\u017Een\u00FDmi organokovov\u00FDmi konjug\u00E1ty a farmakologick\u00E9 faktory, kter\u00E9 jsou zodpov\u011Bdn\u00E9 za protin\u00E1dorov\u00E9 \u00FA\u010Dinky v\u010Detn\u011B rozli\u0161en\u00ED a n\u00E1sledn\u00FDch proces\u016F spojen\u00FDch s po\u0161kozen\u00EDm biomakromolekul." . " cellular pharmacology" . . . "Molecular and cellular pharmacology of new conjugated organometalic compound. Relations to development of anticancer drugs."@en . . . "2014-05-19+02:00"^^ . "1"^^ . "Molekul\u00E1rn\u00ED a bun\u011B\u010Dn\u00E1 farmakologie nov\u00FDch konjugovan\u00FDch organokovov\u00FDch slou\u010Denin. Vztah k v\u00FDvoji nov\u00FDch l\u00E9\u010Div proti rakovin\u011B." . . . . . . "2015-04-29+02:00"^^ . . "1"^^ . . "0"^^ . . "1"^^ . . . "2016-05-31+02:00"^^ . " mechanism of action" . "LD14019" . "The main goal of this COST research project will be to increase knowledge and understanding of the design and mechanisms of action of new organometalic conjugates, and to use this enhanced knowledge to develop new classes of organometalic compounds with novel spectra of biomedical activity. Thus, the aim of this project will be to address the clinical need for new therapeutic agents with novel mechanisms of action. Conjugated organometalic compounds offer such possibilities but their fundamental medicinal chemistry has not been sufficiently explored. Advances in cancer therapy rely on gaining a detailed understanding at the molecular and cellular level of the events which can induce therapeutic agents to destroy cancer cells and yet allow normal cells to recover. Unique modes of modification of biomolecules by specifically designed organometallic conjugated compounds and the pharmacological factors responsible for antitumor effects including the recognition and processing of biomacromolecule damage will be studied."@en . "anticancer activity" . "anticancer activity; cellular pharmacology; mechanism of action; DNa binding"@en . . . .